CureDuchenne provided early funding to Edgewise Therapeutics, and we are pleased with their progress as recently shared in their fourth quarter and full year 2024 reports. In Becker muscular dystrophy, […]
CureDuchenne provided early funding to Capricor Therapeutics, and we are pleased to share that the FDA has accepted its Biologics Licenses Application (BLA) seeking approval for Deramiocel to treat cardiomyopathy in […]
CureDuchenne Clinic within the Neuromuscular Program at CHOC Will Expand Access to Exceptional Care, Deliver Cutting-Edge Treatments, and Drive Innovative Research Newport Beach, CA– March 3, 2025– CureDuchenne, a global […]
CureDuchenne was an early funder of Avidity, and today we share an important milestone: Enrollment is now complete for the EXPLORE44-OLE clinical trial. Avidity is pursuing accelerated approval for del-zota […]
As an early funder of Entrada Therapeutics, we are pleased to share that the FDA has removed the clinical hold on ENTR-601-44, the experimental therapeutic designed for individuals with Duchenne […]
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 Solid Biosciences, announced positive initial results from INSPIRE DUCHENNE, their next-generation gene therapy clinical study of […]
Cumberland Pharmaceuticals announced positive cardiac results from Phase 2 trial in Duchenne Cumberland Pharmaceuticals released positive top-line results from its Phase 2 FIGHT DMD trial, a 12-month placebo controlled study […]
As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization in the United Kingdom (UK) to start a Phase 1/2 trial for individuals with Duchenne […]
Upcoming Events Offer Treatment Updates and Essential Resources to Support Families and Enhance Quality of Life NEWPORT BEACH, Calif., January 31, 2025 – CureDuchenne, a global leader in advancing research and […]
